PROTECT YOUR DNA WITH QUANTUM TECHNOLOGY
Orgo-Life the new way to the future Advertising by AdpathwayA systematic review evaluating interventions for delirium superimposed on dementia found that comparative clinical evidence remains sparse, highly heterogeneous, and of low or very low certainty across existing trials. Published in Frontiers in Neuroscience by researchers Octavian Vasiliu, Andrei Gabriel Mangalagiu, and Bogdan Mircea Petrescu from Carol Davila University of Medicine and Pharmacy and the Dr. Carol Davila University Emergency Central Military Hospital in Bucharest, Romania, the synthesis analyzed five full-text randomized controlled trials enrolling a total of 510 participants. Delirium superimposed on dementia represents an acute neuropsychiatric syndrome marked by acute disturbances in attention, environmental awareness, and fluctuating cognitive dysfunction occurring in individuals with pre-existing dementia. Despite the substantial clinical burden associated with the condition—including accelerated functional decline, prolonged hospital stays, high institutionalization rates, and elevated mortality—the investigators concluded that direct trial evidence does not establish any preferred adjunctive treatment, nor does it demonstrate that all adjunctive therapies are ineffective.
To assemble the evidence base, the investigators conducted comprehensive searches across PubMed, Scopus, and the Web of Science Core Collection from database inception through 1 August 2026, supplemented by Google Scholar, citation tracking, reference-list screening, and a targeted search of the China National Knowledge Infrastructure database. The review protocol was prospectively registered in PROSPERO under identifier CRD420261336276. Eligible studies were required to evaluate adults aged 18 years or older with both pre-existing dementia and superimposed delirium confirmed through recognized diagnostic criteria or validated operational instruments. Eligible comparative designs included randomized controlled trials, quasi-randomized trials, and non-randomized comparative intervention studies evaluating pharmacological treatments, structured non-pharmacological interventions, case-management approaches, or multicomponent care programs against usual care, placebo, or active comparators. Studies focused purely on delirium prevention in participants without baseline delirium were excluded, as were uncontrolled feasibility studies, case reports, and animal or mechanistic investigations.
Risk of bias for the included randomized trials was evaluated using the Cochrane RoB 2 tool across domains encompassing randomization processes, deviations from intended interventions, missing outcome data, outcome measurement, and selection of reported results. Certainty of evidence for each outcome was systematically appraised using the Grading of Recommendations Assessment, Development and Evaluation framework across risk of bias, inconsistency, indirectness, imprecision, and publication bias. Because of marked clinical and methodological heterogeneity in diagnostic definitions, intervention components, and measurement instruments, the authors determined that statistical pooling via meta-analysis would be clinically inappropriate and potentially misleading. Consequently, the review synthesized findings narratively under the Synthesis Without Meta-analysis reporting framework.
Non-pharmacological strategies were evaluated in three included randomized trials, comprising two investigations of individualized cognitively stimulating activities and one study of bright light therapy. An early pilot trial conducted by Kolanowski and colleagues examined 16 newly admitted post-acute care patients diagnosed with dementia and at least two Confusion Assessment Method delirium symptoms, assigning 11 participants to individualized cognitive stimulation and 5 to usual care. Assessments conducted daily for up to 30 days indicated less deterioration in physical function and mental status alongside a numerically shorter delirium duration of 3.27 days compared to 7.0 days in the control group, though differences did not achieve statistical significance. The authors judged this pilot as raising some concerns regarding risk of bias due to incomplete reporting of allocation procedures, while its very small sample substantially limited precision.
A subsequent larger single-blind randomized controlled trial by Kolanowski and colleagues enrolled 283 older adults across eight post-acute care facilities who met criteria for dementia and full or subsyndromal delirium, allocating 141 participants to individualized cognitively stimulating activities delivered up to 30 minutes daily, 5 days per week, and 142 to usual care. The intervention did not yield statistically significant improvements in primary delirium endpoints, showing 64.8 percent delirium-free days versus 68.7 percent in usual care, and a mean Delirium Rating Scale score of 10.77 compared to 11.15. Time to first remission was 6.88 days versus 7.39 days, while remission at discharge or completion was 37.68 percent compared to 34.78 percent, and mortality reached 15.4 percent versus 12.5 percent. However, the trial demonstrated secondary benefits, including significantly improved executive function and a shorter mean post-acute facility stay of 36.09 days compared to 53.13 days. Under GRADE assessment, certainty for cognitive stimulation was rated as low due to imprecision and population indirectness stemming from the inclusion of subsyndromal delirium.
The third non-pharmacological trial, conducted by Zou and colleagues, evaluated 69 older patients with Alzheimer disease-related dementia and delirium-related symptoms allocated to 30 minutes of daily morning bright light therapy at a peak intensity of 14,000 lux or dim light control at 50 lux for 4 weeks alongside conventional pharmacotherapy. Sixty-one participants completed the trial. Bright light was associated with lower reported Confusion Assessment Method scores of 17.65 compared to 19.33 in controls, corresponding to a calculated mean difference of minus 1.68 points, and lower Neuropsychiatric Inventory scores of 3.65 versus 8.03, representing a mean difference of minus 4.38 points. The Zarit Caregiver Burden Interview showed a calculated mean difference of minus 0.78 points, which did not establish a conclusive benefit. Risk of bias was rated as high because of unexplained differential attrition, missing allocation concealment details, and inconsistent statistical reporting, resulting in a very low GRADE certainty rating.
Pharmacological interventions were assessed in two Chinese randomized trials evaluating adjunctive agents combined with the atypical antipsychotic quetiapine. Pu and colleagues conducted an open-label multicentre trial across four hospitals in China enrolling 100 older adults meeting ICD-10 criteria for dementia with superimposed delirium, analyzing 49 patients receiving oral Annao tablets at 2.0 grams two to three times daily plus quetiapine and 47 patients receiving quetiapine alone. Annao recipients showed more favorable Delirium Rating Scale and Brief Psychiatric Rating Scale scores on days 3, 6, and 9, but between-group differences ceased to be statistically significant by days 12 and 15. At day 15, the combination group achieved higher Mini-Mental State Examination scores of 8.58 versus 6.72 and lower activities of daily living scores of 38.72 versus 41.66. The review authors assigned a high risk of bias and very low GRADE certainty, noting that the trial was open-label, lacked documented allocation concealment or assessor blinding, excluded four randomized participants, and exhibited unresolved Delirium Rating Scale scoring where scores increased over time despite clinical improvement.
The second pharmacological trial, reported by Mo and colleagues, randomized 42 hospitalized patients with vascular dementia and DSM-IV-defined delirium superimposed on dementia to intravenous naloxone at 4 milligrams daily plus quetiapine or quetiapine alone for 15 days. Combination therapy was associated with higher reported delirium scale scores of 35.45 compared to 33.00, yielding a calculated mean difference of 2.45 points, and higher Mini-Mental State Examination scores of 8.27 versus 6.50. However, activities of daily living scores did not demonstrate a functional advantage, showing an unadjusted mean difference of 1.31 points. Reported adverse events included fatigue or weakness in two combination recipients, excessive sedation in four control recipients, and blood pressure elevations in three combination recipients that resolved following naloxone dose reduction. The review assigned a high risk of bias and very low GRADE certainty because delirium scale scoring and validation were unspecified, allocation safeguards were omitted, assessor blinding was unreported, and statistical reporting contained inconsistencies.
The review also detailed several excluded and contextual studies to clarify the boundaries of direct evidence. A 120-patient randomized trial comparing risperidone and haloperidol by Djokic and colleagues reported similar improvements across antipsychotics, but because it existed solely as an incompletely reported conference abstract lacking group-specific attrition numbers and verified data, it could not be included in the primary synthesis. An investigation by Moretti and colleagues examining rivastigmine in 246 patients with vascular dementia was excluded because the drug was initiated prior to delirium onset, representing a prevention or recurrence trial rather than treatment for established delirium. Additionally, an uncontrolled feasibility study of activity-based occupational therapy by Pozzi and colleagues in 22 nursing-home residents showed improvements in proxy-rated performance but lacked a comparator, preventing causal attribution.
In discussing clinical implications, the authors noted that existing clinical guidelines—including NICE CG103, SIGN 157, and SCCM PADIS recommendations—emphasize prompt recognition, active investigation and treatment of underlying precipitating medical causes, and multicomponent environmental and supportive care. Pharmacological treatments such as antipsychotics are generally reserved for severe distress or imminent risk of harm rather than proven disease-modifying therapies. The review emphasized that current uncertainty regarding experimental adjunctive therapies should not be interpreted as therapeutic futility after delirium onset. Instead, the authors called for rigorously designed multicentre randomized trials featuring strict baseline diagnostic criteria that separate full delirium from subsyndromal states, blinded outcome assessments, intention-to-treat analyses, standardized core outcome sets, and complete reporting of long-term functional and safety outcomes.
Subject of Research: Systematic review of pharmacological and non-pharmacological interventions for delirium superimposed on dementia
Article Title: Pharmacological and non-pharmacological interventions for delirium superimposed on dementia: a systematic review
Article References: Vasiliu, O., Mangalagiu, A. G., & Petrescu, B. M. (2026). Pharmacological and non-pharmacological interventions for delirium superimposed on dementia: a systematic review. Frontiers in Neuroscience, 20, Article 1983338. https://doi.org/10.3389/fnins.2026.1983338
Image Credits: AI Generated
DOI: 10.3389/fnins.2026.1983338
Keywords: delirium superimposed on dementia, systematic review, cognitive stimulation, light therapy, quetiapine, Annao tablets, naloxone, GRADE assessment, Cochrane RoB 2, Confusion Assessment Method, Delirium Rating Scale, Mini-Mental State Examination, post-acute care, neuropsychiatric symptoms, caregiver burden, geriatric psychiatry, vascular dementia, clinical trial methodology


2 days ago
16




















English (US) ·
French (CA) ·